$Trevi Therapeutics(TRVI.US)Haduvio is the core drug of Trevi Therapeutics, targeting unmet clinical needs, especially chronic cough and chronic pruritus.
The global chronic cough treatment market (idiopathic pulmonary fibrosis-related chronic cough) is expected to reach $8 billion by 2030.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments